Therefore, neutralization of IL-1β might not be a beneficial therapeutic target in NASH, and likely does not affect the therapeutic effectiveness of immune checkpoint inhibitors in NASH-induced malignancies. Here, IL1B is linked to metabolic dysfunction-associated steatohepatitis.